Lilly and Merck Lead the Way With Asian FIPNet Strategies

There's a new acronym to learn:FIPNet--for fully integrated pharmaceutical network. Nowhere is the strategy more apparent than in Asia, where Big Pharma hopes to tap into the increasingly high quality research available in India and China--countries that also should prove to be a major source of future customers. Merck and Eli Lilly are two companies leading the FIPNet charge.

Being a FIPCO—a fully integrated pharmaceutical company—is so last century. Increasingly, many pharmas are adopting strategies that rely heavily on collaborations with multiple partners where those allies bear a much greater proportion of the development risk in exchange for a greater share of the economic reward. In the twenty-first century parlance, it’s about FIPNets—fully integrated pharmaceutical networks.

Nowhere is the strategy more apparent than in Asia, where Big Pharma hopes to tap into the increasingly high quality...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo